Neoplasms, Germ Cell and Embryonal

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor

Vorasidenib Expanded Access Program

Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types

Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients

Spanish Series of Patients Treated With the Radionuclide Lutetium177

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

Multicenter Database of Patients With Germ Cell Tumor

External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

Avelumab in Refractory Testicular Germ Cell Cancer.

Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse

Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy

Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients

Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin